Tag: #Global Trends

Swiss pharmaceutical giant Novartis has officially commenced construction of its new global biomedical research center in San Diego, California. This... Read more

The legal friction between Danish pharmaceutical giant Novo Nordisk and telehealth provider Hims & Hers has intensified. Even though Hims... Read more

Pharmaceutical giant Eli Lilly has reinforced its presence in immunology and oncology by announcing two major deals: the acquisition of... Read more

By the end of the 2025 fiscal year, Novartis CEO Vas Narasimhan saw his realized compensation climb by 30% to... Read more

Health authorities in the United Kingdom are closely monitoring 36 infants exhibiting symptoms of gastrointestinal poisoning after consuming recalled formula... Read more

Shares in Novo Nordisk plummeted on February 4, 2026, following a sobering outlook for the coming year. The Danish pharmaceutical... Read more

On February 4, 2026, California-based Eikon Therapeutics successfully raised $381 million in its initial public offering (IPO), marking the third... Read more

Despite facing nearly $16 billion in U.S. revenue erosion for its long-time blockbuster Humira, AbbVie reported a record-breaking $61.1 billion... Read more

On February 2, 2026, SanegeneBio and Genentech (part of the Roche Group) announced a global licensing agreement to advance an... Read more